Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized platform trial of ascorbic acid and lopinavir/ritonavir for high-risk outpatient adults with COVID-19
PACTR202007700757139Phase 2Unknown
- Sponsor
- Cytel
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ascorbic acid and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Cytel. Status: unknown.
02
Drugs
ascorbic acidlopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202007700757139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007700757139.